ACGN · Aceragen, Inc. - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 | Q2 '21 | Q1 '21 | Q4 '20 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - | - | - | - | - |
| R&D | $4.99M | - | $1.47M | $2.71M | $1.78M | - | $3.51M | $3.89M | $6.87M | - |
| SG&A | $4.92M | - | $2.27M | $2.66M | $2.40M | - | $2.33M | $2.47M | $3.16M | - |
| Total Operating Expenses | $23.08M | - | $9.38M | $5.37M | $4.18M | - | $5.97M | $7.56M | $10.03M | - |
| D&A | $3.0K | - | - | - | $4.0K | - | - | - | $100.0K | - |
| Operating Income | ($20.61M) | - | ($9.33M) | ($5.37M) | ($4.18M) | - | ($5.97M) | ($7.56M) | ($10.03M) | - |
| Interest Expense | - | - | - | - | - | - | - | $4.0K | $3.0K | - |
| Income Tax | ($273.0K) | - | ($6.04M) | $0 | $0 | - | $0 | $0 | $0 | - |
| Net Income | ($21.87M) | - | ($3.10M) | ($5.31M) | ($4.18M) | - | ($5.96M) | ($7.56M) | $115.74M | - |
| EPS - Basic | ($2.94) | - | ($0.06) | ($0.10) | ($0.08) | - | ($0.11) | ($0.15) | $2.66 | - |
| EPS - Diluted | ($2.94) | - | ($0.06) | ($0.10) | ($0.08) | - | ($0.59) | ($0.15) | ($0.14) | - |
Balance Sheet
| Line item | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 | Q2 '21 | Q1 '21 | Q4 '20 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $2.12M | $12.04M | $26.80M | $24.48M | $27.99M | $32.55M | $36.60M | $40.59M | $44.54M | $33.23M |
| Accounts Receivable | $2.20M | $4.21M | $1.96M | - | - | - | - | - | - | - |
| Inventory | - | - | - | - | - | - | - | - | - | - |
| Accounts Payable | $3.41M | $5.20M | $6.76M | $148.0K | $240.0K | $565.0K | $276.0K | $184.0K | $185.0K | $329.0K |
| Current Assets | $5.64M | $17.86M | $30.07M | $25.59M | $29.36M | $34.04M | $38.30M | $43.48M | $47.02M | $41.35M |
| Total Assets | $78.49M | $101.11M | $103.68M | $26.31M | $30.13M | $34.86M | $39.18M | $44.41M | $48.01M | $42.40M |
| Current Liabilities | $17.86M | $21.42M | $19.23M | $4.74M | $3.80M | $4.86M | $5.57M | $6.03M | $5.00M | $7.03M |
| Long-term Debt | - | - | $5.94M | - | - | - | - | - | - | - |
| Total Liabilities | $55.94M | $62.17M | $53.74M | $5.17M | $4.29M | $5.41M | $6.17M | $6.68M | $5.70M | $133.57M |
| Stockholders' Equity | $22.55M | $11.83M | $20.77M | $21.13M | $25.84M | $29.45M | $33.01M | $37.73M | $42.30M | ($91.17M) |
| Retained Earnings | ($780.69M) | ($758.82M) | ($748.04M) | ($744.95M) | ($739.64M) | ($735.46M) | ($731.34M) | ($725.38M) | ($717.81M) | ($833.55M) |
Cash Flow
| Line item | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 | Q2 '21 | Q1 '21 | Q4 '20 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | ($9.85M) | - | - | - | ($4.57M) | - | - | - | ($9.59M) | - |
| Investing Cash Flow | - | - | - | - | - | - | - | - | $4.50M | - |
| Financing Cash Flow | ($74.0K) | - | - | - | $16.0K | - | - | - | $16.40M | - |
| CapEx | - | - | - | - | - | - | - | - | - | - |
| Free Cash Flow | - | - | - | - | - | - | - | - | - | - |
Ratios
| Metric | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 | Q2 '21 | Q1 '21 | Q4 '20 |
|---|---|---|---|---|---|---|---|---|---|---|
| Profitability | ||||||||||
| Gross margin | - | - | - | - | - | - | - | - | - | - |
| Operating margin | - | - | - | - | - | - | - | - | - | - |
| EBITDA margin | - | - | - | - | - | - | - | - | - | - |
| Net margin | - | - | - | - | - | - | - | - | - | - |
| Free cash flow margin | - | - | - | - | - | - | - | - | - | - |
| FCF / Net income | - | - | - | - | - | - | - | - | - | - |
| R&D / Revenue | - | - | - | - | - | - | - | - | - | - |
| SG&A / Revenue | - | - | - | - | - | - | - | - | - | - |
| Effective tax rate | - | - | - | - | - | - | - | - | 0.0% | - |
| Return on assets | -27.9% | - | -3.0% | -20.2% | -13.9% | - | -15.2% | -17.0% | 241.1% | - |
| Return on equity | -97.0% | - | -14.9% | -25.1% | -16.2% | - | -18.1% | -20.0% | 273.6% | - |
| Return on invested capital | - | - | -27.6% | - | - | - | - | - | - | - |
| Liquidity | ||||||||||
| Current ratio | 0.32 | 0.83 | 1.56 | 5.40 | 7.73 | 7.00 | 6.88 | 7.21 | 9.41 | 5.89 |
| Quick ratio | 0.32 | 0.83 | 1.56 | 5.40 | 7.73 | 7.00 | 6.88 | 7.21 | 9.41 | 5.89 |
| Cash ratio | 0.12 | 0.56 | 1.39 | 5.17 | 7.37 | 6.69 | 6.58 | 6.73 | 8.92 | 4.73 |
| Leverage | ||||||||||
| Debt / Equity | - | - | 0.29 | - | - | - | - | - | - | - |
| Debt / Assets | - | - | 0.06 | - | - | - | - | - | - | - |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Interest coverage | - | - | - | - | - | - | - | -1889.3x | -3342.3x | - |
| Equity multiplier | 3.48 | 8.55 | 4.99 | 1.24 | 1.17 | 1.18 | 1.19 | 1.18 | 1.13 | -0.47 |
| Liabilities / Assets | 0.71 | 0.61 | 0.52 | 0.20 | 0.14 | 0.16 | 0.16 | 0.15 | 0.12 | 3.15 |
| Efficiency | ||||||||||
| Asset turnover | - | - | - | - | - | - | - | - | - | - |
| Inventory turnover | - | - | - | - | - | - | - | - | - | - |
| Days sales outstanding | - | - | - | - | - | - | - | - | - | - |
| Days inventory outstanding | - | - | - | - | - | - | - | - | - | - |
| Days payable outstanding | - | - | - | - | - | - | - | - | - | - |
| Cash conversion cycle | - | - | - | - | - | - | - | - | - | - |
| Valuation | ||||||||||
| P / E | - | - | - | - | - | - | - | - | - | - |
| P / B | - | - | - | - | - | - | - | - | - | - |
| P / S | - | - | - | - | - | - | - | - | - | - |
| EV / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Growth | ||||||||||
| Revenue growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| Revenue CAGR (3y) | - | - | - | - | - | - | - | - | - | - |
| Revenue CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Gross profit growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| Operating income growth (YoY) | -392.8% | - | -56.3% | 29.0% | 58.3% | - | 20.3% | 5.7% | 23.8% | - |
| Net income growth (YoY) | -423.4% | - | 48.0% | 29.8% | - | - | 71.0% | 68.8% | 1212.7% | - |
| EPS growth (YoY) | -3575.0% | - | 89.8% | 33.3% | 42.9% | - | - | 79.2% | - | - |
| EPS CAGR (3y) | - | - | - | - | - | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| FCF growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| FCF CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Book value growth (YoY) | -12.8% | -59.8% | -37.1% | -44.0% | -38.9% | - | - | - | - | -716.4% |
Peer comparison
Same SIC group: Biological Products, (No Diagnostic Substances)
Comparing Aceragen against the 5 most active filers in the same SIC group.